177Lu-FAP-2286 Targeted Radionuclide Therapy in Advanced Pancreatic Cancer: A Real-World Retrospective Salvage Study.

The therapy exhibited a favorable safety profile; the patient-level incidence of treatment-emergent bone marrow suppression and hepatotoxicity was 18.2% and 27.3%, respectively.

Significant improvements were documented in NRS pain scores (P<0.001), KPS (P<0.001), and multiple EORTC QLQ-C30 functional domains.

In the intent-to-treat population, the disease control rate (disease control rate) was 40.9% (9/22), whereas a higher disease control rate of 75% (9/12) was observed in the evaluable subgroup.

Univariate analysis showed that post-treatment KPS improvement was associated with OS (HR=0.30, P=0.018) and PFS (HR=0.35, P=0.043).